Gilead collaborates with Glympse Bio on NASH diagnostic test

Gilead Sciences and Glympse Bio Inc. are to partner on developing a non-invasive diagnostic test for the fatty liver disease non-alcoholic steatohepatitis (NASH). Glympse uses a set of synthetic, in vivo biomarkers made of compounds engineered to react to the presence of specific diseases within the body. Those reactions produce chemical signals that are collected and analysed after the injection passes through the patient’s system. Glympse hopes that its artificial biomarkers will outperform the body’s natural ones, and Gilead plans to use these biomarkers to identify the stages and progression of NASH, and also to assist in the detection of early signs of a patient’s response to treatment. The tests will be used in the initial screenings of clinical trial participants, and also throughout studies in Gilead’s NASH development program.
Gilead’s senior vice president of liver diseases, Mani Subramanian, said: “By utilising this innovative technology, we hope to better characterize this complex disease and improve our understanding of how our compounds impact disease progression.”